Associate Vice President - Aging Research

Eli Lilly and Company•Us, IN

About The Position

The Associate Vice President, Aging owns Lilly’s aging strategy within Mobility and Healthy Aging (MHA), a new pillar within Cardiometabolic Research focused on age-related loss of function in bone, muscle, joint, and the biology of aging. The role is the senior scientific voice for the strategy, providing deep expertise in aging biology—including cellular senescence, proteostasis, mitochondrial dysfunction, chronic inflammation, and epigenetic and molecular measures of biological age—to guide target and mechanism selection, patient and clinical settings, capability development, and portfolio alignment. The position is accountable for the scientific credibility of aging-directed targets and assets in the MHA portfolio and for translating aging biology into medicines with definable patient populations and measurable endpoints. The leader works across bone, muscle, and joint biology to identify interventions that address aging mechanisms and produce functional benefits across tissues, while collaborating with scientists and leaders throughout Lilly on approaches to aging and age-related disorders. This role combines scientific leadership, external influence, and portfolio strategy. It guides aging research and development programs, biomarkers, models, assays, and translational tools; represents Lilly in the aging research community; and advises on external opportunities and collaborations. The role also brings clinical and regulatory judgment to strategy, recognizing that aging itself is not an approvable indication and that programs must be grounded in appropriate tissue and disease contexts.

Requirements

  • PhD or MD.
  • At least 10 years of experience in drug discovery and/or development in the pharmaceutical or biotechnology industry.
  • Recognized expertise in aging biology, demonstrated by a substantial record of peer-reviewed publications, invited presentations, and standing in the aging research community.
  • Thorough understanding of drug discovery and development, including regulatory and intellectual property considerations, with a record of contributions to INDs and/or NDAs.
  • Demonstrated strategic thinking across targets, patient populations, clinical development, and the regulatory environment.
  • Track record of successfully leading, building, and developing scientific and/or project teams in an industry setting.
  • Demonstrated ability to drive results in a fast-paced matrix environment, including newly formed organizations without established precedent or processes.
  • Ability to translate dense scientific and clinical evidence into decision-grade recommendations for senior research and commercial leadership.
  • Excellent written and verbal communication skills.

Nice To Haves

  • Hands-on experience establishing, validating, and interpreting in vitro aging systems, including cellular senescence and stress-induced models, replicative aging, primary and iPSC-derived cells from aged or disease donors, organoid and co-culture systems, and omics-based aging signatures.
  • Hands-on experience with in vivo aging models, including naturally aged rodents, progeroid and genetic models, and diet- or injury-based models of age-related functional decline.
  • Ability to design in vivo studies accounting for age, sex, strain, cohort size, and duration, and to interpret functional, histological, and molecular endpoints.
  • Ability to judge whether standard field readouts—including senescence markers, epigenetic age, lifespan, and healthspan measures—are decision-grade, and to distinguish biomarkers of aging from biomarkers of mechanism or clinical benefit.
  • Ability to develop target-specific screening cascades and critical paths in aging, including stage-specific go/no-go criteria, assay sequencing, translatable pharmacodynamic markers, and data packages to advance targets from hypothesis through candidate nomination and into the clinic.
  • Established external network across academic aging centers, geroscience consortia, and the longevity biotech ecosystem.
  • Experience with biomarker strategy and qualification, particularly measures of biological age or functional reserve.
  • Familiarity with the regulatory endpoint landscape for function and healthspan and the practical implications of surrogate endpoint qualification.
  • Passion for learning, openness to new opportunities and entrepreneurial thinking.

Responsibilities

  • Own the scientific position of the Aging area, including target credibility, mechanisms, translational risk, and model strategy across internal programs and external opportunities.
  • Set and defend scientific standards for aging-directed target entry and candidate selection, distinguishing well-supported mechanisms.
  • Serve as Lilly’s internal scientific authority on biological aging biomarkers, including their validation status and practical utility in development decisions.
  • Help build, lead, and develop the scientific team and shape the capabilities MHA needs in aging.
  • Partner with Bone, Muscle, and Joint leads to ground aging mechanisms in tissue-level function, and collaborate with other Lilly therapeutic areas where aging biology intersects their portfolios.
  • Ensure MHA has the assays, models, and translational tools to evaluate aging targets credibly; assess existing models, the need for aged and functional in vivo systems, and where new capabilities are required.
  • Represent Lilly as a scientific voice in aging biology and geroscience with key opinion leaders, academic centers, societies, and consortia.
  • Serve as an internal reference on aging science for research and commercial leaders across Lilly.
  • Lead and participate in advisory boards, scientific sessions, and external target reviews and diligence, and help shape the field’s direction.
  • Build and sustain external scientific relationships that provide visibility into emerging aging science, including in the longevity biotech and investment ecosystem.
  • Own and shape Lilly’s aging strategy within CMR, defining tissue and disease contexts that can translate aging mechanisms into approvable medicines and where Lilly should or should not pursue opportunities.
  • Bring clinical and regulatory judgment to strategy, accounting for the fact that aging is not an approvable indication.
  • Set the scientific framework for external aging opportunities; define compelling opportunities, assess them, advise on portfolio fit, and support integration into the portfolio.
  • Prepare teams for governance interactions and communicate strategy to senior management and cross-functional partners.
  • Serve on Joint Steering Committees or as a board observer to shape the scientific direction of collaborations and new companies.

Benefits

  • Company bonus eligibility, depending in part on company and individual performance.
  • Eligibility to participate in a company-sponsored 401(k).
  • Pension.
  • Vacation benefits.
  • Eligibility for medical, dental, vision, and prescription drug benefits.
  • Flexible benefits, including healthcare and/or dependent day care flexible spending accounts.
  • Life insurance and death benefits.
  • Certain time-off and leave-of-absence benefits.
  • Well-being benefits, including an employee assistance program, fitness benefits, and employee clubs and activities.
  • Employee resource groups open to all employees.
© 2026 Teal Labs, Inc
Privacy PolicyTerms of Service